VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT
出版年份 2013 全文链接
标题
VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT
作者
关键词
-
出版物
LEUKEMIA
Volume 28, Issue 4, Pages 928-934
出版商
Springer Nature
发表日期
2013-09-18
DOI
10.1038/leu.2013.267
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease
- (2013) Evangelos Terpos et al. JOURNAL OF CLINICAL ONCOLOGY
- Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma
- (2013) X Leleu et al. LEUKEMIA
- Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
- (2012) M. Cavo et al. BLOOD
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial
- (2011) Hye Jin Kim et al. ANNALS OF HEMATOLOGY
- Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma
- (2011) Michel Delforge et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid
- (2010) E. Terpos et al. ANNALS OF ONCOLOGY
- Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
- (2010) F. van Rhee et al. BLOOD
- A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients
- (2010) M. Zangari et al. HAEMATOLOGICA
- Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents
- (2010) Asher A. Chanan-Khan et al. JOURNAL OF CLINICAL ONCOLOGY
- Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
- (2010) Marco Ladetto et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of complete response in multiple myeloma
- (2009) J.-L. Harousseau et al. BLOOD
- Dickkopf-1: a suitable target for the management of myeloma bone disease
- (2009) Maria Gavriatopoulou et al. EXPERT OPINION ON THERAPEUTIC TARGETS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More